When is a bone scan study appropriate in asymptomatic men diagnosed with prostate cancer?

Asian Journal of Andrology

Volumn 10, Issue 6, 2008, Pages 890-895

  Pal, Raj P ^a   Thiruudaian, Thivyaan ^a   Khan, Masood A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

OXIDRONATE TECHNETIUM TC 99M; PROSTATE SPECIFIC ANTIGEN; DIAGNOSTIC AGENT; MEDRONATE TECHNETIUM TC 99M; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; GLEASON SCORE; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; SCORING SYSTEM; ANALYSIS OF VARIANCE; BONE; BONE TUMOR; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; RETROSPECTIVE STUDY; SCINTISCANNING;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BONE AND BONES; BONE NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TECHNETIUM TC 99M MEDRONATE;

EID: 59449098845     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00427.x     Document Type: Article

References (23)

1. Office for National Statistics, Cancer Statistics registrations. Registrations of cancer diagnosed in 2005, England Series MB1 no. 35. London: Office for National Statistics, 2007.
2. Office for National Statistics. Mortality Statistics: Cause, 2005, Series DH2 no. 23. London: Office for National Statistics, 2007.
3. Schröder FH, Wildhagen MF. Rotterdam Study Group of the 'European Randomised Study of Screening for Prostate Cancer' (ERSPC). Screening for prostate cancer: Evidence and perspectives. BJU Int 2001; 88: 811-7.
4. Landis SH, Murray T, Bolden S, Wingo PA. Cancer Statistics, 1999. CA Cancer J Clin 1999; 49: 8-29.
5. McGregor B, Tulloch AG, Quinlan MF, Lovegrove F. The role of bone scanning in the assessment of prostatic carcinoma. Br J Urol 1978; 50: 178-81.
6. Varenhorst E, Alund G, Lindström E, Manson JC. Bone marrow aspiration biopsy and bone scanning in the staging of prostatic cancer. Br J Urol 1983; 55: 534-7.
7. Goodman CM, Cumming JA, Ritchie AW, Chishom GD. Prognostic value of raised prostatic acid phosphatase and negative skeletal scintigraphy in prostate cancer. Br J Urol 1991; 67: 622-5.
8. Haukaas S, Roervik J, Halvorsen OJ, Foelling M. When is bone scintigraphy necessary in the assessment of newly diagnosed, untreated prostate cancer? Br J Urol 1997; 79: 770-6.
9. Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: Prostate specific antigen is superior to all other clinical parameters. J Urol 1991; 145: 313-8.
10. Shih WJ, Wierzbinski B, Collins J, Magoun S, Chen IW, Ryo UY. Serum osteocalcin measurements in prostate carcinoma patients with skeletal deposits shown by bone scintigram: Comparison with serum PSA/PAP measurements. J Nucl Med 1990; 31: 1486-9.
11. Kosuda S, Yoshimura I, Aizawa T, Koizumi K, Akakura K, Kuyama J, et al. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan. Cancer 2002; 94: 964-72.
12. Oesterling JE, Martin SK, Bergstralh EJ, Lowe FC. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer. JAMA 1993; 269: 57-60.
13. Gleave ME, Coupland D, Drachenberg D, Cohen L, Kwong S, Goldenberg SL, et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-12.
14. Rudoni M, Antonini G, Favro M, Baroli A, Brambilla M, Cardani G, et al. The clinical value of prostate-specific antigen and bone scintigraphy in the staging of patients with newly diagnosed, pathologically proven prostate cancer. Eur J Nucl Med 1995; 22: 207-11.
15. Ataus S, Citçi A, Alici B, Onder AU, Sönmezoǧlu K, Erözenci A, et al. The value of serum prostate specific antigen and other parameters in detecting bone metastases in prostate cancer. Int. Urol Nephrol 1999; 31: 481-9.
16. Rydh A, Tomic R, Tavelin B, Hietala SO, Damber JE. Predictive value of prostate-specific antigen, tumour stage and tumour grade for the outcome of bone scintigraphy in patients with newly diagnosed prostate cancer. Scand J Urol Nephrol 1999; 33: 89-93.
17. Bruwer G, Heyns CF, Allen FJ. Influence of local tumour stage and grade on reliability of serum prostate-specific antigen in predicting skeletal metastases in patients with adenocarcinoma of the prostate. Eur Urol 1999; 35: 223-7.
18. O'Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP. Broadening the criteria for avoiding staging bone scans in prostate cancer: A retrospective study of patients at the Royal Marsden Hospital. BJU Int 2003; 92: 685-9.
19. Lee N, Fawaaz R, Olsson CA, Benson MC, Petrylak DP, Schiff PB, et al Which patients with newly diagnosed prostate cancer need a radionuclide bone scan? An analysis based on 631 patients. Int J Radiat Oncol Biol Phys 2000; 48: 1443-6.
20. Kemp PM, Maguire GA, Bird NJ. Which patients with prostatic carcinoma require a staging bone scan? Br J Urol 1997; 79: 611-4.
21. Ishizuka O, Tanabe T, Nakayama T, Kawakami M, Kinebuchi Y, Nishizawa O. Prostate-specific antigen, Gleason sum and clinical T stage for predicting the need for radionuclide bone scan for prostate cancer patients in Japan. Int J Urol 2005; 12: 728-32.
22. Wolff JM, Zimny M, Borchers H, Wildberger J, Buell U, Jakse G. Is prostate-specific antigen a reliable marker of bone metastasis in patients with newly diagnosed cancer of the prostate? Eur Urol 1998; 33: 376-81.
23. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80.